![]() |
|
|
Vol. 289, Issue 3, 1434-1446, June 1999
Behavioral Biology Research Center, Department of Psychiatry and
Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore,
Maryland
The benzodiazepine receptor ligand U-78875
[3-(5-cyclopro pyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)imidazol(1,5-a)quinoxalin-4(5H)-o-ne] was studied in rats trained to discriminate i.p. 1.0 mg/kg lorazepam, 1.0 mg/kg diazepam, or 10 mg/kg pentobarbital, and baboons trained to
discriminate oral 1.8 mg/kg lorazepam or 10 mg/kg pentobarbital. U-78875 doses were 0.01 to 10 mg/kg i.p. in rats and 0.32 to 56 mg/kg
orally in baboons. U-78875 occasioned drug-appropriate responding in
pentobarbital-trained (ED50 = 1.8 mg/kg) and
diazepam-trained (ED50 = 0.056 mg/kg) rats, but it occurred
in only one pentobarbital-trained baboon and not in the majority of
lorazepam-trained baboons or rats. In baboons that generalized to
U-78875, discriminative effects were antagonized by flumazenil. The
interaction of U-78875 with pentobarbital, diazepam, and lorazepam
revealed further differences in its behavioral effects. U-78875
potentiated the effects of pentobarbital, even in baboons that did not
generalize to U-78875, but U-78875 had little effect in combination
with diazepam. In lorazepam-trained animals that did not generalize to
it, U-78875 antagonized lorazepam's effects, but U-78875 neither
antagonized nor potentiated lorazepam in animals that did generalize to
U-78875. Thus, although U-78875 generally functioned as a
benzodiazepine agonist in pentobarbital- and diazepam-trained animals,
its unique effects in lorazepam-trained animals appear to reflect its
in vitro profile as a partial agonist.
This article has been cited by other articles:
![]() |
S. C. Licata, D. M. Platt, J. M. Cook, P. V. V. S. Sarma, G. Griebel, and J. K. Rowlett Contribution of GABAA Receptor Subtypes to the Anxiolytic-Like, Motor, and Discriminative Stimulus Effects of Benzodiazepines: Studies with the Functionally Selective Ligand SL651498 [6-Fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihydro-1H-pyridol[3,4-b]indol-1-one] J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1118 - 1125. [Abstract] [Full Text] [PDF] |
||||